RNXT Stock Overview
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
RenovoRx, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.34 |
52 Week High | US$4.60 |
52 Week Low | US$0.53 |
Beta | 1.12 |
1 Month Change | 2.29% |
3 Month Change | -41.48% |
1 Year Change | -60.24% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -81.54% |
Recent News & Updates
Recent updates
Is RenovoRx (NASDAQ:RNXT) In A Good Position To Invest In Growth?
Mar 31Companies Like RenovoRx (NASDAQ:RNXT) Could Be Quite Risky
Dec 16RenovoRx reports Q2 results
Aug 15Is RenovoRx (NASDAQ:RNXT) In A Good Position To Deliver On Growth Plans?
Aug 04RenovoRx names new finance CFO
Jul 19RenovoRx (NASDAQ:RNXT) Is In A Good Position To Deliver On Growth Plans
Mar 16We Think RenovoRx (NASDAQ:RNXT) Can Afford To Drive Business Growth
Nov 30Shareholder Returns
RNXT | US Biotechs | US Market | |
---|---|---|---|
7D | -8.8% | 0.9% | 0.4% |
1Y | -60.2% | 10.3% | 28.8% |
Return vs Industry: RNXT underperformed the US Biotechs industry which returned 10.3% over the past year.
Return vs Market: RNXT underperformed the US Market which returned 28.8% over the past year.
Price Volatility
RNXT volatility | |
---|---|
RNXT Average Weekly Movement | 22.9% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RNXT's share price has been volatile over the past 3 months.
Volatility Over Time: RNXT's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 10 | Shaun Bagai | https://renovorx.com |
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors.
RenovoRx, Inc. Fundamentals Summary
RNXT fundamental statistics | |
---|---|
Market cap | US$23.22m |
Earnings (TTM) | -US$9.16m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.5x
P/E RatioIs RNXT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RNXT income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$9.16m |
Earnings | -US$9.16m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.54 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did RNXT perform over the long term?
See historical performance and comparison